Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?

Nature Reviews Neurology

Volumn 11, Issue 12, 2015, Pages 669-670

  Gandy, Sam ^a   Sano, Mary ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; SOLANEZUMAB; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; GENE EXPRESSION; GENE MUTATION; HUMAN; NEUROPSYCHOLOGICAL TEST; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS;

EID: 84949318426     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.218     Document Type: Short Survey

References (10)

1. Siemers, E. R. et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. http://dx.doi.org/10.1016/j.jalz.2015.06.1893.
2. Liu, E. et al. Amyloid-11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85, 692-700 (2015).
3. Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924-1938 (2015).
4. Jack, C. R. Jr et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81, 1732-1740 (2013).
5. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from A1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448-6453 (1998).
6. Schöll, M. et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 79, 229-236 (2012).
7. Lim, Y. Y. et al. Effect of amyloid on memory and decline from preclinical to clinical Alzheimer's disease. Brain 137, 221-231 (2014).
8. Ramanan, V. K. et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain http://dx.doi.org/10.1093/brain/awv231.
9. Lambert, J.-C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45, 1452-1458 (2013).
10. Sperling, R. A. et al. The A4 study: stopping AD before symptoms begin Sci. Transl. Med. 6, 228fs13 (2014).